关注IBD | 优信合生团队全英文论文网络首发

Inflammatory bowel disease (IBD) is a complex, chronic intestinal inflammatory disorder that primarily includes Crohn’s disease (CD) and ulcerative colitis (UC). Although traditional antibiotics and immunosuppressants are known as the most effective and commonly used treatments, some limitations may be expected, such as limited efficacy in a small number of patients and gut flora disruption. A great many research studies have been done with respect to the etiology of IBD, while the composition of the gut microbiota is suggested as one of the most influential factors. Along with the development of synthetic biology and the continuing clarification of IBD etiology, broader prospects for novel approaches to IBD therapy could be obtained. This study presents an overview of the currently existing treatment options and possible therapeutic targets at the preclinical stage with respect to microbial synthesis technology in biological therapy. This study is highly correlated to the following topics: microbiota-derived metabolites, microRNAs, cell therapy, calreticulin, live biotherapeutic products (LBP), fecal microbiota transplantation (FMT), bacteriophages, engineered bacteria, and their functional secreted synthetic products for IBD medical implementation. Considering microorganisms as the main therapeutic component, as a result, the related clinical trial stability, effectiveness, and safety analysis may be the major challenges for upcoming research. This article strives to provide pharmaceutical researchers and developers with the most up-to-date information for adjuvant medicinal therapies based on synthetic biology.

• 
• 
•  
• 左对齐
  居中
  右对齐

2022年8月10日，由苏州优信合生技术有限公司研发团队撰写的英文综述文章《Opportunities and challenges for synthetic biology in the therapy of inflammatory bowel disease》(《合成生物学在肠道炎症性疾病疗法中的机遇与挑战》)网络首发。本文致力于为药物研究人员和开发人员提供基于合成生物学的IBD辅助药物治疗的最新信息。

Inflammatory bowel disease (IBD)是一种复杂的、慢性的肠道炎症性疾病, 主要包括克罗恩病(CD)和溃疡性结肠炎(UC)。IBD的发病机制仍在研究中, 而肠道菌群失调、宿主基因多态性与突变、免疫系统内稳态平衡的中断和非遗传因素是已知的最普遍共识。

虽然传统的抗生素和免疫抑制剂被认为是最有效和最常用的治疗方法, 但预期可能会有一些局限性, 如对少数患者的有限功效和肠道菌群的破坏。关于IBD病因学的研究有很多, 而肠道菌群的成分被认为是最具影响力的因素之一。随着合成生物学的发展和IBD病因学的持续阐明, IBD新疗法更广阔的可能性可被获得。

本文概述了关于微生物合成技术在生物治疗中临床前期的现有疗法选择和可能的治疗靶点:

1) 对IBD发病机制中微生物衍生代谢物 (胆汁酸、短链脂肪酸 (SCFAs)、色氨酸和琥珀酸)的研究;

2) microRNA在IBD的诊断、预防和治疗中的关键作用；

3) 骨髓间充质干细胞以其良好的组织再生能力和免疫调节能力而被广泛应用于IBD治疗;

4) 钙网蛋白在免疫抑制剂和微生物药物相关的IBD治疗中的应用潜力;

5) 被认为是下一代益生菌的活体生物药 (LBP), 包括菌种 (乳酸乳球菌、酵母菌、嗜黏蛋白阿克曼氏菌、大肠杆菌和鸡尾酒梭状芽胞杆菌), 工程菌产物 (沙门氏菌效应蛋白AvrA), 粪菌移植 (FMT) 和噬菌体治疗等。